Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma

被引：0
|
作者：
A Ray
D S Das
Y Song
T Hideshima
Y-T Tai
D Chauhan
K C Anderson
机构：
[1] The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center,Department of Medical Oncology
[2] Dana-Farber Cancer Institute,undefined
[3] Harvard Medical School,undefined
来源：
Leukemia | 2018年 / 32卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：843 / 846
页数：3
相关论文
共 50 条
  • [21] Development of novel combination cancer immunotherapy using anti-PD-1 and anti-PD-L1 antibody
    Hasegawa, Hirotaka
    Sugiyama, Daisuke
    Kanda, Mitsuro
    Hayashi, Masamichi
    Tanaka, Chie
    Yamada, Suguru
    Nakayama, Goro
    Koike, Masahiko
    Nomoto, Shuji
    Fujiwara, Michitaka
    Kodera, Yasuhiro
    Nishikawa, Hiroyoshi
    CANCER SCIENCE, 2021, 112 : 741 - 741
  • [22] Inhibition of A2AR induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical and clinical studies
    Willingham, Stephen
    Hotson, Andrew
    Ho, Po
    Choy, Carmen
    Walter, Kim
    Yusko, Erik
    Benzeno, Sharon
    Laport, Ginna
    Miller, Richard
    McCaffery, Ian
    CANCER RESEARCH, 2017, 77
  • [23] A novel PIKfyve inhibitor, CB371 enhances the anti-tumor activity of anti-PD-1 antibody by modulating cancer immunity.
    Uno, Yuko
    Matsumoto, Hirokazu
    Endo, Hiroko
    Katoh, Yuki
    Yaguchi, Tomonori
    Kawakami, Yutaka
    Sawa, Masaaki
    CANCER SCIENCE, 2022, 113 : 1626 - 1626
  • [24] A Novel Anti-PD-L1 Antibody Exhibits Antitumor Effects on Multiple Myeloma in Murine Models via Antibody-Dependent Cellular Cytotoxicity
    Ahn, Jae-Hee
    Lee, Byung-Hyun
    Kim, Seong-Eun
    Kwon, Bo-Eun
    Jeong, Hyunjin
    Choi, Jong Rip
    Kim, Min Jung
    Park, Yong
    Kim, Byung Soo
    Kim, Dae Hee
    Ko, Hyun-Jeong
    BIOMOLECULES & THERAPEUTICS, 2021, 29 (02) : 166 - 174
  • [25] The immunocytokine PD1-IL2v overcomes immune checkpoint resistance, and combination with an anti-PD-L1 antibody further enhances its anti-tumor activity.
    Wullschleger, Stephan
    Tichet, Melanie
    Codarri-Deak, Laura
    Umana, Pablo
    Klein, Christian
    Hanahan, Douglas
    CANCER RESEARCH, 2021, 81 (13)
  • [26] HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer
    Fukumoto, Takeshi
    Fatkhutdinov, Nail
    Zundell, Joseph A.
    Tcyganov, Evgenii N.
    Nacarelli, Timothy
    Karakashev, Sergey
    Wu, Shuai
    Liu, Qin
    Gabrilovich, Dmitry I.
    Zhang, Rugang
    CANCER RESEARCH, 2019, 79 (21) : 5482 - 5489
  • [27] HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression
    Xiaolei Li
    Xiao Su
    Rui Liu
    Yongsha Pan
    Jiankai Fang
    Lijuan Cao
    Chao Feng
    Qianwen Shang
    Yongjing Chen
    Changshun Shao
    Yufang Shi
    Oncogene, 2021, 40 : 1836 - 1850
  • [28] HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression
    Li, Xiaolei
    Su, Xiao
    Liu, Rui
    Pan, Yongsha
    Fang, Jiankai
    Cao, Lijuan
    Feng, Chao
    Shang, Qianwen
    Chen, Yongjing
    Shao, Changshun
    Shi, Yufang
    ONCOGENE, 2021, 40 (10) : 1836 - 1850
  • [29] Notch signaling inhibitor and anti-PD-L1 antibody combination therapies decelerate tumor progression in pancreatic cancer
    Dai, Hongmei
    Hong, Xiafei
    Huang, Dan
    Wu, Huanwen
    Wang, Xianze
    Chen, Hao
    Jiang, Rui
    Chen, Wenyan
    Zhao, Yupei
    Wu, Wenming
    JOURNAL OF PANCREATOLOGY, 2021, 4 (02) : 106 - 114
  • [30] Notch signaling inhibitor and anti-PD-L1 antibody combination therapies decelerate tumor progression in pancreatic cancer
    Dai Hongmei
    Hong Xiafei
    Huang Dan
    Wu Huanwen
    Wang Xianze
    Chen Hao
    Jiang Rui
    Chen Wenyan
    Zhao Yupei
    Wu Wenming
    胰腺病学杂志（英文）, 2021, 04 (02) : 106 - 114
12345